FDA Expands ASCENIV™ Label to Include Pediatric Patients Two Years and Older
ADMA sits 47% above its 52-week low of $7.21.
Summary
ADMA Biologics announced that the FDA has approved the expansion of the label for its product, ASCENIV™, to include pediatric immune compromised patients two years of age and older. This approval significantly broadens the addressable market for ASCENIV™, which was previously indicated only for patients aged 12 years and older. This regulatory milestone is a substantial positive catalyst, as it allows ADMA to target a new, younger patient demographic, potentially driving increased sales and market penetration for a key product. Traders will be watching for future sales data and management's updated revenue projections related to this expanded indication.
At the time of this announcement, ADMA was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.21 to $24.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.